Bioject Enters Into Agreement With Fondaco PTE LTD For Distribution Of Full
Line Of Needle Free Injection Devices In Asia
Agreement advances Bioject's global market expansion strategy through
Fondaco's established medical device marketing and distribution networks in
countries including Singapore, Malaysia and Indonesia
TIGARD, Ore., Oct. 23, 2013
TIGARD, Ore., Oct. 23, 2013 /PRNewswire/ --Bioject Medical Technologies Inc.
(OTC Pink: BJCT), a leading developer and manufacturer of needle-free
injection technology, today announced that it has entered into a distribution
agreement with Fondaco PTE, LTD, a premier medical supplies company based in
Singapore. Under the terms of this agreement, Fondaco will be the exclusive
distributor of Bioject's commercial needle-free injection products in
Singapore, Indonesia, and Malaysia.
Products positioned for distribution through this agreement include the full
portfolio of Bioject technologies including the Biojector® 2000 needle-free
injection system and theBioject® ZetaJet™ portable injector. In September
2013, Bioject also announced an international distribution agreement with
iHealthnet LLC for distribution of Bioject products in markets including South
Asia, India and the Middle East.
"We have seen significant demand for advanced needle-free technologies in
global markets including Asia in recent years. Through collaboration with
established industry leaders such as Fondaco, we will be ideally positioned to
expand our product marketing focus in this region in the years ahead.
Together we have the full range of expertise and insight to bring the
significant advantages of needle-free drug delivery to millions more patients
in the years ahead," said Mark Logomasini, President and CEO of Bioject.
The global injectable drug delivery technologies market was valued at $22.5
billion in 2012, and is expected to reach $43.3 billion by 2017. Recent
reports indicate that the market for injectable technologies is positioned to
grow rapidly in Asia in the coming decade, based in part on expanding access
to healthcare services and the growing number of patients in emerging markets
affected by diabetes and other diseases that involve treatment with injectable
Bioject's advanced needle-free technology works by forcing liquid medication
at high speed through a tiny orifice held against the skin. The diameter of
the orifice is smaller than the diameter of a human hair. This creates an
ultra-fine stream of medicine able to penetrate skin without use of a needle.
Bioject's technology is available for use with a wide range of injectable
drugs and has the ability to deliver medicine at a range of depths and
injection volumes. For instance, the Biojector 2000 can deliver intramuscular
or subcutaneous injections up to 1 mL in volume. Bioject technologies also
include auto-disable features that can prevent inappropriate reuse of
"By combining Bioject's outstanding technology and products with our
established marketing and distribution network and our extensive experience in
meeting the needs of pharma and life sciences companies in Asia, this
collaboration positions us to rapidly expand market penetration for Bioject
products throughout Singapore, Malaysia and Indonesia. Working together we
will also play an important role in helping more life science companies as
well as patients and clinicians in these markets to recognize the improved
convenience, safety and comfort that Bioject needle-free drug delivery
offers," said Jane Fonda, Chief Executive Officer of Fondaco.
About Bioject Medical Technologies Inc.
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a
developer and manufacturer of needle-free injection therapy systems (NFITS).
To meet global demand for needle free injection technologies, Bioject is
focused on developing mutually beneficial agreements with leading
pharmaceutical, biotechnology, and veterinary companies, as well as research,
global health and government organizations.
Readers and potential investors are cautioned that an investment in the
Bioject's securities involve an EXTREMELY high degree of risk. Such risks
include, without limitation, the risk that the distribution agreement will not
be successful due to the time required in obtaining government clearances and
the risk that the Company may be unable to comply with the extensive
government regulations applicable to the international business. Bioject (OTC
Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find
Real-Time quotes and market information for the Company on
For more information about Bioject, visit www.bioject.com
SOURCE Bioject Medical Technologies Inc.
Contact: Bioject Medical Technologies Inc., Mark Logomasini, President and
CEO, 503-692-8001; Christine Farrell, Vice President of Finance, 503-692-8001
Press spacebar to pause and continue. Press esc to stop.